AstraZeneca plc (AZN) Price Target Cut to GBX 5,600 by Analysts at Deutsche Bank


The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. Deutsche Bank's price objective suggests a potential upside of 43.33% from the stock's current price.



from Biotech News